Olutasidenib

Rigel announces publication of data on REZLIDHIA(Olutasidenib) in post-venetoclax patients with mutant IDH1 AML in Leukemia & Lymphoma.
REZLIDHIA (Olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1), in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.